Preclinical Characterization of SDFZ‐8, a Highly Potent HDAC1 Inhibitor, for Cancer Immunotherapy
MedComm · 2025-12 · 6 (12)
DOI: 10.1002/mco2.70500 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm, online erschienen am 18.11.2025. Verfasst von Yi Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine Shandong…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The histone deacetylases (HDACs) family plays a critical role in tumorigenesis and has been identified as having a significant impact on tumor immunity. Herein, we employed a fragment‐centric structure‐based design platform, leading to the discovery of SDFZ‐8 as a highly potent HDAC1 inhibitor (IC 50 = 0.4 nM). SDFZ‐8 exhibits strong antiproliferative effects by enabling histone acetylation and inducing cell apoptosis. Crucially, SDFZ‐8 treatment led to a significant enhancement of antitumor immunity, as evidenced by increased activation of T cells, enhanced polarization of M1‐type macrophages, improved antigen presentation, and alleviation of the immunosuppressive tumor microenvironment. Specifically, we observed that SDFZ‐8 notably upregulated the expression of PD‐L1 in both tumor cells and tumor‐infiltrating lymphocytes, which is closely associated with its inhibition against HDAC1. Of particular interest, combining SDFZ‐8 with PD‐L1 blockade resulted in a synergistic antitumor effect surpassing that of either monotherapy. Taken together, our findings establish SDFZ‐8 as a novel HDAC1 inhibitor that concurrently targets tumor cells and immune evasion mechanisms, providing a rational combinatorial strategy to enhance cancer immunotherapy efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicinal Chemistry State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead C…
- Department of Pharmacy Shandong Provincial Hospital Affiliated to Shandong First Medical University Ji'nan Shandong China.
- Shandong Cancer Hospital and Institute Shandong First Medical University Ji'nan Shandong China.
- Department of Immunopharmaceutical Sciences School of Pharmaceutical Science Cheeloo College of Medicine, Shandong University Ji'nan Shandong China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhou, Y., Du, J., Li, X., Zhao, H., Xue, J., Liu, Y., Yang, X., Yu, J., Hou, X., & Fang, H. (2025). Preclinical Characterization of SDFZ‐8, a Highly Potent HDAC1 Inhibitor, for Cancer Immunotherapy. MedComm, 6(12). https://doi.org/10.1002/mco2.70500
Vancouver
Zhou Y, Du J, Li X, Zhao H, Xue J, Liu Y, et al. Preclinical Characterization of SDFZ‐8, a Highly Potent HDAC1 Inhibitor, for Cancer Immunotherapy. MedComm. 2025;6(12). doi:10.1002/mco2.70500
BibTeX
@article{Zhou2025,
author = {Zhou, Yi and Du, Jintong and Li, Xue and Zhao, Huajun and Xue, Junxin and Liu, Yuchen and Yang, Xinying and Yu, Jinming and Hou, Xuben and Fang, Hao},
title = {Preclinical Characterization of SDFZ‐8, a Highly Potent HDAC1 Inhibitor, for Cancer Immunotherapy},
journal = {MedComm},
year = {2025},
volume = {6},
number = {12},
doi = {10.1002/mco2.70500}
}
EUVIMED